Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38a and BRD4. (2019)
Attributed to:
Defining the role of ERK5 kinase and ERK5 transcriptional activities in cell migration and EMT using novel ERK5 inhibitors
funded by
BBSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.ejmech.2019.05.057
PubMed Identifier: 31212132
Publication URI: http://europepmc.org/abstract/MED/31212132
Type: Journal Article/Review
Volume: 178
Parent Publication: European journal of medicinal chemistry
ISSN: 0223-5234